PRCT Reaffirms 2026 Guidance in Q3 Report

What happened

PROCEPT BioRobotics reported third quarter 2026 financial results on November 4, 2026, and reaffirmed its full-year 2026 guidance, including revenue of $390-410 million, U.S. procedures of 54,000-56,000, and adjusted EBITDA loss of $30-35 million. The reaffirmation signals management's confidence in hitting targets despite ongoing competitive pressure from prostate artery embolization (PAE) and upcoming CMS reimbursement changes. However, the press release does not provide Q3 specifics such as revenue, procedure growth, or consumables pull-through, which are critical for assessing whether utilization reacceleration is occurring. Investors will need to parse the earnings call for evidence that handpiece demand is catching up to system placements, a key concern from prior quarters. Overall, the news is a neutral checkpoint that removes near-term guidance-cut risk but leaves the core thesis dependent on fourth-quarter execution and the final CMS 2027 physician fee schedule rule.

Implication

The removal of guidance-cut risk is a small positive, but the market remains focused on whether consumables growth can converge with procedure growth, which has lagged placements in recent quarters. The final CMS 2027 rule due in November will clarify 2027 reimbursement economics and could materially impact Aquablation adoption if PAE gains an advantage. With the stock trading near $19, the risk/reward is balanced, and we would need to see a sustained increase in U.S. handpiece pull-through or evidence of HYDROS driving higher procedures per account before turning more constructive. Conversely, a break below $17 would offer a more attractive entry if the competitive backdrop remains stable. In the meantime, we await the Q3 earnings call details on key metrics such as U.S. procedure counts, handpiece ASP, and any management commentary on PAE competitive losses.

Thesis delta

The investment thesis remains WAIT, as the Q3 guidance reaffirmation is consistent with our prior view but does not yet provide the required proof of utilization reacceleration. The next major catalyst is the November CMS 2027 final rule, which will determine whether Aquablation economics deteriorate relative to PAE. We will only consider upgrading if subsequent quarterly reports show consumables growth converging toward procedure growth and no evidence of reimbursement-driven share loss.